Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The provided content mostly matches labeled indication and 50 mg dosing, but the response contains substantial, unnecessary label assessment text that is not an FDA-label-supported “response” to a specific query, and it omits evaluating multiple material safety elements (e.g., contraindications/pregnancy, hepatic risk, anticoagulant monitoring).
Category Scores
Accurate Statements
CASODEX 50 mg daily is indicated for use in combination therapy with an LHRH analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
Supported by Section 1 (INDICATIONS AND USAGE).
The recommended dose for CASODEX in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food.
Supported by Section 2.1 (Recommended Dose and Schedule).
CASODEX 150 mg daily is not approved for use alone or with other treatments.
Supported by Section 1 and Section 14.2 (not approved statements for 150 mg).
Unsupported Statements
“Supported: yes / Contradicted: no / Mentioned: yes” and the accompanying label-assessment narrative that frames the evaluation as if it were a complete alignment check across contraindications/warnings/interactions, despite not actually verifying those sections.
Not a claim about the drug itself, but the assessment asserts completeness without providing label-backed verification for multiple safety categories.
Contradictions
Important Omissions
Contraindications evaluation (e.g., hypersensitivity; contraindication in pregnant women; statement that CASODEX has no indication for women).
Importance:
Moderate
Warnings/precautions evaluation (e.g., hepatitis/severe liver injury timing; glucose tolerance considerations in combination with LHRH agonists; hemorrhage/PT-INR monitoring with coumarin anticoagulants).
Importance:
Moderate
Drug interaction details evaluation (e.g., CYP 3A4 substrate caution; coumarin anticoagulant displacement and PT/INR monitoring).
Importance:
Moderate
Adverse reaction evaluation (e.g., hot flashes as most frequent clinical trial adverse reaction; postmarketing interstitial lung disease and hemorrhage/PT-INR increase).
Importance:
Moderate
Specific populations guidance evaluation beyond the brief mention of 150 mg: pregnancy, reproductive potential contraception timing, hepatic/renal impairment caution statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response accurately addresses indication and 50 mg dosing, but it does not actually verify multiple material safety elements (contraindications, key warnings/precautions, interactions, and key adverse reactions) that are important for safe use. This creates risk that critical label safety content may be missed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Assessment focuses on indication/dosing but does not substantively evaluate multiple material FDA label safety and population sections.
Suggested Improvement
Limit the conclusion strictly to what was verified (indication and approved dosing) and/or explicitly check and report alignment for contraindications, boxed/major warnings and precautions, drug interactions, and key adverse reactions as supported by the provided label excerpts.